0
Research Letter |

Autoantibodies Present Before Symptom Onset in Primary Sjögren Syndrome

Roland Jonsson, DMD, PhD1; Elke Theander, MD, PhD2; Bitte Sjöström, MSc3; Karl Brokstad, PhD1; Gunnel Henriksson, MD, PhD3
[+] Author Affiliations
1Broegelmann Research Laboratory, University of Bergen, Bergen, Norway
2Department of Rheumatology, Lund University, Malmö, Sweden
3Department of Laboratory Medicine Malmö, Lund University, Malmö, Sweden
JAMA. 2013;310(17):1854-1855. doi:10.1001/jama.2013.278448.
Text Size: A A A
Published online

Extract

Autoantibodies are characteristic of primary Sjögren syndrome1 and may be involved in its pathogenesis.2 We investigated autoantibodies present before symptom onset in patients with Sjögren syndrome because data on this issue are limited.

Section Editor: Jody W. Zylke, MD, Senior Editor.

Article InformationCorresponding Author: Gunnel Henriksson, MD, PhD, Lund University, Jan Waldenströms St 59, 20502 Malmö, Sweden (gunnel.henriksson@med.lu.se).

Author Contributions: Dr Henriksson had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Jonsson and Theander contributed equally to the article.

Study concept and design: Jonsson, Theander, Henriksson.

Acquisition of data: Jonsson, Theander, Sjöström, Brokstad, Henriksson.

Analysis and interpretation of data: Jonsson, Theander, Sjöström, Brokstad, Henriksson.

Drafting of the manuscript: Jonsson, Theander, Brokstad, Henriksson.

Critical revision of the manuscript for important intellectual content: Jonsson, Theander, Sjöström, Brokstad, Henriksson.

Statistical analysis: Theander, Sjöström.

Obtained funding: Jonsson, Theander, Henriksson.

Administrative, technical, or material support: Jonsson, Theander, Sjöström, Brokstad, Henriksson.

Study supervision: Jonsson, Theander, Henriksson.

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Theander reported serving on advisory boards for Roche and Pfizer; receiving payment for lectures from Roche; and receiving reimbursement for travel expenses from Roche and Pfizer. No other disclosures were reported.

Funding/Support: This study was supported by grants from the Malmö University Hospital Foundation, the Malmö University Hospital Cancer Foundation, the Swedish Rheumatism Association, the Strategic Research Program at Helse Bergen, the Regional Health Authority for Western Norway, the Broegelmann Foundation, and the Foundations of Kock, Österlund, and Gustaf V.

Role of the Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We are grateful to Peter Olsson, MD (Department of Rheumatology, Lund University, Malmö, Sweden), for assistance with acquisition of data and Bo Cederholm, MD, PhD (Clinical Immunology Laboratory, Skåne University Hospital, Lund, Sweden), for access to laboratory facilities for the analysis of rheumatoid factor. No compensation was received by either of these individuals.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.
Cumulative Number of Patients With Primary Sjögren Syndrome With Autoantibodies Before Clinical Onset
Graphic Jump Location

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();